Cyclopharm Limited · ASX:CYC
Cyclopharm — Shareholder Meeting (May 2023)
31 slides from Cyclopharm's shareholder meeting presentation, May 16, 2023
Slide 1: Cyclopharm 2023 Annual General Meeting
For personal use only CYCLOPHARM 2023 Annual General Meeting 16 May 2023 1
Slide 2: Safe Harbour Statement
Certain views expressed here contain information derived from publicly available sources that have not been independently verified. The presentation includes certain statements, estimates and projections with respect For personal use only to the anticipated future financial performance of Cyclopharm
Slide 3: Welcome
For personal use only Welcome Mr David Heaney 3
Slide 4: Chairman's Address
For personal use only CHAIRMAN’S ADDRESS Mr David Heaney 4
Slide 5: Technegas Around the World
TECHNEGAS® AROUND THE WORLD For personal use only Technegas® was introduced to the medical community in 1986 Technegas® revenues are generated in over 64 countries via a combination of direct and distributor sales models Over 4.6 million patient procedures to date 5
Slide 6: A World Leading Diagnostic Imaging Company
A World Leading Diagnostic Imaging Company Recovery in FY 2022 continued from initial COVID-19 impact in primary country markets with 1 record sales of $23.2m. (Technegas sales $13.66m up 4.1% - Third-party sales $9.22 up 124% compared to 2021) For personal use only Continued underlying profitabilit
Slide 7: Managing Director's Address
For personal use only MANAGING DIRECTOR’S ADDRESS Mr James McBrayer 7
Slide 8: 2022 – Delivering on our growth objectives
2022 – Delivering on our growth objectives For personal use only 1 Grow – Grow Technegas Sales 2 Expand – Expand the Use of Technegas 3 Leverage – Leverage core strengths to continue to accelerate our third-party distribution business 4 Develop – Identify, develop and commercialise complementary inn
Slide 9: 2022 Financial Highlights
For personal use only $22.88 million - an increase of 32% Sales Revenue Third Party Distribution $9.22 million of third‐party distribution revenue, 2022 Net Loss After Tax more than double of FY22 $6.61 million loss including US-FDA related Financial expenses USFDA Expenses $2.97 million Highlights
Slide 10: 2022 Operating Highlights
Sales increased 4.1% to $13.76 m For personal use only Technegas Third Party Distribution $9.22 million of third‐party distribution revenue, more than double of FY22 2022 Regulatory Renewals All regulatory renewals in existing 64 country Operating Indication Expansion markets maintained Continued pr
Slide 11: Immediate Pulmonary Embolism Market Opportunity
600K Nuclear Medicine Ventilation 15%/600k Procedures p.a. • The Company estimates 4,000,000 patient procedures are conducted in For personal use only the USA per annum to diagnose pulmonary embolism (15% Nuclear Medicine – 85% CTPA) • ~600,000 Nuclear Medicine Ventilation pre-COVID procedures equal
Slide 12: USA Customer Demand Established
USA Customer Demand Established The Wait Is Nearly Over Technegas generator placement strategy targeting rapid deployment and drive highly profitable consumable sales For personal use only 1 Multiple letters from leading clinicians, front-line workers and the SNMMI have petitioned the USFDA for the
Slide 13: USA Commercialisation Pathway
Regulatory Clinical ➢ CRL Reply submitted 30 March 2023 ➢ Key Opinion Leaders engaged ➢ USFDA Target Review Date 29 Sept 2023 ➢ Recruit Chief Medical Officer. ➢ Site Inspection scheduled 31 July – 11 Aug ➢ R&D Programs Beyond PE Underway 2023 For personal use only Commercial 3PL ➢ >400 Expressions o
Slide 14: Three Value Horizons
THREE VALUE HORIZONS Horizon 3 THE FUTURE IS NOW >8 Years to Reach Potential use only Horizon 2 Innovate Beyond PE Globally 1 Clinical trial program – commenced 2016 3 to 8 Years Horizon 1 HALF BILLION personalVALUE Convert CTPA KOL Engagement – detailing directly to in PE Diagnosis combined suffere
Slide 15: Indication Expansion – The Importance, Urgency & Opportunity Beyond PE
Indication Expansion – The Importance, Urgency & Opportunity Beyond PE For personal use only 1 Lung Disease in 2019 accounted for 6 million deaths worldwide (12% of all deaths) 2 COPD and Lower Respiratory Infections and Lung Cancer will be the 3rd, 4th and 6th largest causes of death by 2030. “Over
Slide 16: Beyond PE applications of V/Q SPECT(/CT)
Beyond PE applications of V/Q SPECT(/CT) For personal use only Diagnosis and Preoperative Preoperative Planning radiation Advanced approach Use of alternate Diagnosis and follow-up of assessment of assessment of therapy to target to phenotyping isotopes to monitoring of Pulmonary homogeneous lung re
Slide 17: Beyond Pulmonary Embolism Initiatives Underway
Beyond Pulmonary Embolism Initiatives Underway 6 Cyclopharm sponsored Beyond PE clinical trials For personal use only 1 Hunter Medical Research Institute (Newcastle, AU): Diagnosis and response to therapy in severe asthma and COPD1 100 Patient Study * 100% Recruited * Imaging Analysis Underway * Cas
Slide 18: Key Catalysts for the Next Years
KEY Catalysts for the Next 2 Years For personal use only 1 FDA approval for Technegas expected late 2023 2 First sales in US announce (shortly after approval) 3 Ongoing updates on Generators placed in US Clinical proof of concept & validation in new substantive respiratory 4 indications 18
Slide 19: Cyclopharm Investment Case
CYCLOPHARM INVESTMENT CASE For personal use only Profitable and First in Class Recurring Revenue USFDA Approval Technegas Product Growing MedTech Established Gold Standard From single patient Set to quadruple the size expansion Underlying business Proprietary product sales to consumables of the exis
Slide 20: Business Q&A
For personal use only 20 BUSINESS Q&A
Slide 21: Formal Business
For personal use only FORMAL BUSINESS Mr David Heaney 21
Slide 22: 2023 AGM – Formal Business Resolutions
2023 AGM – Formal Business Resolutions For personal use only 1 Financial – (b) Remuneration Report 2 Election of Mr Kevin Barrow as Director 3 Election of Professor Gregory King as Director 4 Re-election of Mr David J Heaney as Director 5 Share Buy-back 6 Approval of Non-executive Director Remunerat
Slide 23: Resolution 1(b): Remuneration Report
CYC AGM 2023 Resolutions For personal use only 1(b) That the Remuneration Report as set out in the Annual Report of the Company for the financial year ended 31 December 2022 be adopted. Resolution For Against Discretionary Abstain Remuneration Report 43,522,977 71,966 22,406,049 96,750 Questions? 23
Slide 24: Election of Mr Kevin Barrow as Director
CYC AGM 2023 Resolutions For personal use only 2 That, for the purposes of ASX Listing Rule 14.4 and for all other purposes, Mr Kevin Barrow, being eligible and having consented to act, be elected as a Director of the Company. Resolution For Against Discretionary Abstain Election of Mr Kevin Barrow
Slide 25: Election of Professor Gregory King as Director
CYC AGM 2023 Resolutions For personal use only 3 That, for the purposes of ASX Listing Rule 14.4 and for all other purposes, Professor Gregory King, being eligible and having consented to act, be elected as a Director of the Company. Resolution For Against Discretionary Abstain 3 Election of Profess
Slide 26: Re-election of Mr D J Heaney as Director
CYC AGM 2023 Resolutions For personal use only 4 That for the purposes of ASX Listing Rule 14.4 and for all other purposes, Mr David James Heaney, who retires at the close of this Annual General Meeting and, being eligible, and having consented to act, be re-elected as a Director of the Company. Res
Slide 27: Share Buy-back
CYC AGM 2023 Resolutions For personal use only 5 That pursuant to and in accordance with section 257C(1) of the Corporations Act, as amended, and for all other purposes, the shareholders approve, with effect from when the Directors make the relevant announcement to the ASX, the on-market buy-back of
Slide 28: Approval of Non-executive Director Remuneration
CYC AGM 2023 Resolutions For personal use only 6 That for the purposes of Listing Rule 10.17 and for all other purposes, the shareholders of the Company approve the increase of the maximum aggregate amount payable to non-executive directors by way of directors' fees from $350,000 to $450,000. Resolu
Slide 29: Renewal of Proportional Takeover Bid Provisions
CYC AGM 2023 Resolutions For personal use only 7 That, for the purposes of sections 136(2) and 648G of the Corporations Act, the proportional takeover provisions in rule 164 of the Constitution be and are hereby adopted for the three year period from 16 May 2023 up to and including 16 May 2026. Spec
Slide 30: 2023 AGM – Proxy Summary
2023 AGM – Proxy Summary For personal use only Resolution For Against Discretionary Abstain 1(b) Remuneration Report 43,522,977 71,966 22,406,049 96,750 2 Election of Mr Kevin Barrow 46,206,739 99,777 22,417,663 0 as Director 3 Election of Professor Gregory 46,204,339 102,177 22,417,663 0 King as Di
Slide 31: Thank You
For personal use only T H A N K YO U 31